Table 3.
Compound | Y | PR transactivation assay | Metabolic stability assay | ||
---|---|---|---|---|---|
IC50 [nm] | Efficacy [%] | F max Human [%] | F max Rat [%] | ||
14 | 0.50 | 100 | n.d. | n.d. | |
15 | 8.0 | 100 | 98 | 100 | |
16 | 3.5 | 100 | 57 | 88 | |
17 | 0.01 | 100 | 31 | 34 | |
18 (vilaprisan) | 0.09 | 100 | 94 | 87 | |
19 | 0.9 | 100 | 75 | 69 |